Pasi A. Jänne, MD, PhD, Dana-Farber Cancer Institute
Advertisement
Articles by Pasi A. Jänne, MD, PhD, Dana-Farber Cancer Institute
Advertisement
Latest Updated Articles
Rapid Readouts: Phase 1/2 KRYSTAL-1 TrialPublished: November 18th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
2
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
3
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
4
Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies
5